23 reports of this reaction
1.7% of all METHYLERGONOVINE MALEATE reports
#12 most reported adverse reaction
CYANOSIS is the #12 most commonly reported adverse reaction for METHYLERGONOVINE MALEATE, manufactured by Lupin Pharmaceuticals,Inc.. There are 23 FDA adverse event reports linking METHYLERGONOVINE MALEATE to CYANOSIS. This represents approximately 1.7% of all 1,362 adverse event reports for this drug.
Patients taking METHYLERGONOVINE MALEATE who experience cyanosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYANOSIS is a less commonly reported adverse event for METHYLERGONOVINE MALEATE, but still significant enough to appear in the safety profile.
In addition to cyanosis, the following adverse reactions have been reported for METHYLERGONOVINE MALEATE:
The following drugs have also been linked to cyanosis in FDA adverse event reports:
CYANOSIS has been reported as an adverse event in 23 FDA reports for METHYLERGONOVINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYANOSIS accounts for approximately 1.7% of all adverse event reports for METHYLERGONOVINE MALEATE, making it a notable side effect.
If you experience cyanosis while taking METHYLERGONOVINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.